

Mannheim / Naples, March 27, 2014

Letter of invitation

Educational day for European fellows; May 5 -6, 2014; Naples, Italy

Dear Colleague,

Following the success of the past five editions of the EUTOS Naples Fellows Day on CML, and with the aim of allowing young hematologists to exchange knowledge with leading experts, the **European LeukemiaNet** through **EUTOS for CML** and a grant from **Novartis Oncology**, are pleased to announce the sixth edition of "Chronic Myeloid Leukemia: current treatment paradigms and future perspectives" that will take place on **May 5 -6, 2014** in Naples, Italy.

This educational day is dedicated to young European hematology fellows, to provide the most up-to-date information in the field of CML treatment.

The program will combine presentations, case studies, workshop and interactive Q&A sessions hosted by a group of leading hematologists, and an opportunity for European fellows to discuss CML treatment.

For your information, an agenda and list of faculty for this event are attached.

We are delighted to offer one fellow from your institution the opportunity to participate in this educational meeting: their logistical costs will be covered through the support of "EUTOS in CML".

To register to this event, the participant should complete the electronic form accessing the following web link: www.gcoeurope.com/CMLNaples2014 (please, cut and paste or type the address into your web browser in case the link doesn't work). Deadline to register is **Friday, April 11, 2013**.

Please, note that space is limited. We will confirm attendance based on a first come first served basis.

For further information or questions regarding registration and logistics, please, contact Adela Marcos from the logistic agency at CMLNaples2014@gcoeurope.com.

Yours sincerely,

Prof. Fabrizio Pane

University of Naples, Italy

Prof. Rüdiger Hehlmann

University of Heidelberg, Germany

Mlleuaeuc





Chronic Myeloid Leukemia:

Current treatment paradigms and future perspectives

An educational day for European fellows on behalf of EUTOS for CML 5-6 May 2014, Naples, Italy

Agenda - Day 1

Nr.	Time	Min	Торіс	Speaker
	13.30 h - 13.40 h	00:10	Scope of the course	Fabrizio Pane
			Session 1: The CML and its treatment in newly diagnose	d patients
1	13.40 h - 14.00 h	00:20	The CML: Epidemiology and clinical features	Bengt Simonsson
2	14.00 h - 14.20 h	00:20	Up-to-date aspects of cellular and molecular pathogenesis of CML: The chronic phase and the role of tyrosine kinases. The mechanisms of transformation to advanced phases	Giuseppe Saglio
3	14.20 h - 14.40 h	00:20	Long term experience with imatinib therapy as first line treatment: Efficacy, tolerability and treatment optimization issues	Rüdiger Hehlmann
4	14.40 h - 15.00 h	00:20	Current treatment strategies of newly diagnosed CML patients: New generation TKIs and other drugs (or IFN) for front-line treatment	Andreas Hochhaus
	15.00 h - 15.30 h	00:30	Questions and answers	All
	15.30 h - 16.00 h	00:30	Refreshment break	
			Session 2: Resistance to the treatment and the advanced	phases of CML
5	16.00 h - 16.20 h	00:20	Rescue treatment strategies: Treatments for resistant patients	Gianantonio Rosti
6	16.20 h - 16.40 h	00:20	Treatment optimization of CML Mutation profiles of resistant patients	Simona Soverini
7	16.40 h - 17.00 h	00:20	TKI side effect management and quality of life in CML patients under TKI treatment	Juan Luis Steegmann
8	17.00 h - 17.20 h	00:20	Treatment of advanced phases and the allogeneic SCT in CML	Susanne Sauβele
9	17.20 h - 17.40 h	00:20	The chronic myeloid leukemia features and treatment problems in childhood and elderly patient	Delphine Rea
	17.40 h - 18.10 h	00:30	Questions and answers	All
	18.10 h - 18.20 h	00:10	Closing remarks	Rüdiger Hehlmann





Chronic Myeloid Leukemia:

Current treatment paradigms and future perspectives

An educational day for European fellows on behalf of EUTOS for CML 5-6 May 2014, Naples, Italy

Agenda - Day 2

Nr.	Time	Min	Торіс	Speaker
	8.30 h - 8.40 h	00:10	Scope of the course	Fabrizio Pane
			Session 3: CML Managements and the ELN recommendate	tions
10	8.40 h - 9.00 h	00:20	Management of CML treatment in 2014: The ELN recommendations	Michele Baccarani
11	9.00 h - 9.20 h	00:20	Monitoring of CML: Tools, time-points, correct use and limits of methodologies	Nick Cross
12	9.20 h - 9.40 h	00:20	Prognostication in CML: Baseline and treatment-related factors	Martin Müller
13	9.40 h - 10.00 h	00:20	Mechanisms of resistance to TKIs: Treatment discontinuation	Philippe Rousselot
	10.00 h - 10.30 h	00:30	Questions and answers	All
			Session 4: Clinical case-based session	
14	10.30 h - 10.50 h	00:20	Clinical case 1 Take home messages and discussion	Benjamin Hanfstein Martin Müller
15	10.50 h - 11.10 h	00:20	Clinical case 2 Take home messages and discussion	Luigia Luciano Fabrizio Pane
16	11.10 h - 11.30 h	00:20	Clinical case 3 Take home messages and discussion	Gianantonio Rosti Michele Baccarani
	11.30 h - 12.00 h	00:30	Refreshment break	
			Session 5: Future perspectives on CML	
17	12.00 h - 12.20 h	00:20	The role of CML advocacy group	Felice Bombaci
18	12.20 h - 12.40 h	00:20	The remaining challenges to cure CML: The Ph+ stem cells	François Xavier Mahon
19	12.40 h - 13.00 h	00:20	A look to the future: Novel drugs in CML	Stephen O'Brien
	13.00 h - 13.25 h	00:25	Questions and answers	All
	13.25 h - 13.30 h	00:05	Meeting summary	Rüdiger Hehlmann and Fabrizio Pane